arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

SAB Biotherapeutics, Inc.

SABS

$3.89 ▲ +0.06 (+1.43%) at close

7 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

SAB Biotherapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $75.1M

Dividend Yield —

Revenue Growth N/M

Op. Margin None

ROIC -32.3% ↗

FCF / Share $-2.37 ↗

Trailing P/E 17.7x

Price / Book 1.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$13.27M

↑ +138.9% —

Operating Margin Operating profit as % of sales

-121.0%

↓ -449.9% —

FCF / Share Free cash flow per share

$-2.37

↑ +36.7% —

Health Breakdown

Returns

Financial Health ↓

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	N/M	-40.9% Weak ↑ Weak Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-612%)	-90.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1233%)	-60.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-859%)	10.2% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+28%)	—	—
EPS Growth YoY (%)	N/M	51.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-77.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	31.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—
Net Income Growth YoY (%)	N/M	19.2% Good ↑ Good Improving Year-over-year change in net income	-125.1% Weak Weak Year-over-year change in net income	-9.3% Weak Weak Year-over-year change in net income	N/M	—	—
FCF Growth YoY (%)	36.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	18.5% Good ↑ Good Improving Year-over-year change in free cash flow	22.1% Good ↑ Good Improving Year-over-year change in free cash flow	-79.7% Weak Weak Year-over-year change in free cash flow	-205.1% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	—	-72.1% Weak Weak Compound annual revenue growth over 3 years	-65.6% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	—	—	-121.0% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-906%)	-22.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-247%)	37.2% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+148%)	—
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	-78.4% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-753%)	-28.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-335%)	36.4% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+204%)	—
FCF Margin (%) (%)	—	—	—	-107.2% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-14.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-4.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	-3.44x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	1.37x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-0.14x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-32.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-130.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-66.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-93.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	52.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-28.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-97.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	36.4% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	8.8% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-42%)	-131.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-976%)	-73.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-591%)	-60.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-502%)	-44.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-396%)	51.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+244%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	-202.26x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-114.75x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-120.77x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-95.89x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-45.48x Weak Weak Operating income divided by interest expense Optimal: > 5x	43.82x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-10.50M	$-8.90M	$-56.57M	$-15.05M	$-33.21M	$-12.61M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.00	$0.14	$0.41	$5.49	$22.27	$21.75	—
Basic EPS, GAAP (USD)	$0.22	$-3.68	$-7.64	$-4.31	$-6.30	$7.90	—
Free Cash Flow per Share (USD)	$-2.37	$-3.74	$-4.59	$-5.89	$-3.28	$-1.07	—
Book Value per Share (USD)	$3.18	$2.80	$6.21	$6.16	$8.86	$15.02	—
Tangible Book Value per Share (USD)	$3.18	$2.80	$6.21	$6.16	$8.86	$15.02	—
Basic Weighted Avg Shares (shares)	19.31M	9.26M	5.52M	4.35M	2.73M	2.54M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$90.37M	$15.81M	$48.09M	$7.10M	$23.74M	$23.39M	—
Total Equity (USD)	$151.49M	$25.97M	$57.30M	$31.06M	$38.55M	$39.01M	$7.69M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$1.32M	$2.24M	$23.90M	$60.88M	$55.24M	—
Depreciation Expense (USD)	$2.99M	$4.71M	$3.65M	$3.17M	$1.49M	$383.14K	—
Net Income, GAAP (USD)	$13.27M	$-34.11M	$-42.19M	$-18.74M	$-17.14M	$20.12M	—
Operating Cash Flow (USD)	$-44.78M	$-34.29M	$-25.12M	$-23.46M	$1.99M	$10.00M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 23 quarters

SAB Biotherapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare SABS with peers